Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review

International Journal of Antimicrobial Agents

Volumn 47, Issue 4, 2016, Pages 259-268

  Alobaid, Abdulaziz S ^a   Hites, Maya ^b   Lipman, Jeffrey ^a,c   Taccone, Fabio Silvio ^b   Roberts, Jason A ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ERASME HOSPITAL   (Belgium)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antifungal; Fluconazole; Morbidly obese patients; Non obese patients; Obesity; Pharmacodynamics

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; FLUCONAZOLE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MICAFUNGIN; MOXIFLOXACIN; PIPERACILLIN; TOBRAMYCIN; VANCOMYCIN;

AREA UNDER THE CURVE; BODY SIZE; BODY WEIGHT; CRITICALLY ILL PATIENT; DISEASE CLASSIFICATION; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; OBESITY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; VOLUME OF DISTRIBUTION; CHEMICAL PHENOMENA; CHEMISTRY; CRITICAL ILLNESS;

ANTI-INFECTIVE AGENTS; CRITICAL ILLNESS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; OBESITY;

EID: 84960510918     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.01.009     Document Type: Review

References (90)

1. Y. Sasabuchi, H. Yasunaga, H. Matsui, A.T. Lefor, H. Horiguchi, K. Fushimi, and et al. The dose-response relationship between body mass index and mortality in subjects admitted to the ICU with and without mechanical ventilation Respir Care 60 2015 983 991
2. M.V. Viana, R.B. Moraes, A.R. Fabbrin, M.F. Santos, V.B. Torman, S.R. Vieira, and et al. Contrasting effects of preexisting hyperglycemia and higher body size on hospital mortality in critically ill patients: a prospective cohort study BMC Endocr Disord 14 2014 50
3. A. El-Solh, P. Sikka, E. Bozkanat, W. Jaafar, and J. Davies Morbid obesity in the medical ICU Chest 120 2001 1989 1997
4. N. Bercault, T. Boulain, K. Kuteifan, M. Wolf, I. Runge, and J-C. Fleury Obesity-related excess mortality rate in an adult intensive care unit: a risk-adjusted matched cohort study Crit Care Med 32 2004 998 1003
5. R. Huttunen, and J. Syrjänen Obesity and the risk and outcome of infection Int J Obes (Lond) 37 2013 333 340
6. J. Bishara, R. Farah, J. Mograbi, W. Khalaila, O. Abu-Elheja, M. Mahamid, and et al. Obesity as a risk factor for Clostridium difficile infection Clin Infect Dis 57 2013 489 493
7. I. Baik, G.C. Curhan, E.B. Rimm, A. Bendich, W.C. Willett, and W.W. Fawzi A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women Arch Intern Med 160 2000 3082 3088
8. M.E. Falagas, and M. Kompoti Obesity and infection Lancet Infect Dis 6 2006 438 446
9. J.A. Roberts, and J. Lipman Pharmacokinetic issues for antibiotics in the critically ill patient Crit Care Med 37 2009 840 851 quiz 859
10. A.A. Udy, J.A. Roberts, and J. Lipman Clinical implications of antibiotic pharmacokinetic principles in the critically ill Intensive Care Med 39 2013 2070 2082
11. R.A. Blouin, J.H. Kolpek, and H.J. Mann Influence of obesity on drug disposition Clin Pharm 6 1987 706 714
12. R.J. Bosma, J.A. Krikken, J.J. Homan van der Heide, P.E. de Jong, and G.J. Navis Obesity and renal hemodynamics Contrib Nephrol 151 2006 184 202
13. F.S. Taccone, P.F. Laterre, T. Dugernier, H. Spapen, I. Delattre, X. Wittebole, and et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock Crit Care 14 2010 R126
14. G.L. Drusano Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' Nat Rev Microbiol 2 2004 289 300
15. J.A. Roberts, and J. Lipman Antibacterial dosing in intensive care Clin Pharmacokinet 45 2006 755 773
16. S.I. Blot, F. Pea, and J. Lipman The effect of pathophysiology on pharmacokinetics in the critically ill patient - concepts appraised by the example of antimicrobial agents Adv Drug Deliv Rev 77 2014 3 11
17. S. Finfer, R. Bellomo, N. Boyce, J. French, J. Myburgh, and R. Norton A comparison of albumin and saline for fluid resuscitation in the intensive care unit N Engl J Med 350 2004 2247 2256
18. M. Ulldemolins, J.A. Roberts, J. Rello, D.L. Paterson, and J. Lipman The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients Clin Pharmacokinet 50 2011 99 110
19. M. Carlier, F.S. Taccone, M. Beumier, L. Seyler, F. Cotton, F. Jacobs, and et al. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy Int J Antimicrob Agents 46 2015 413 419
20. A.A. Udy, J.P. Baptista, N.L. Lim, G.M. Joynt, P. Jarrett, L. Wockner, and et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations Crit Care Med 42 2014 520 527
21. A.A. Udy, J.A. Roberts, R.J. Boots, D.L. Paterson, and J. Lipman Augmented renal clearance Clin Pharmacokinet 49 2010 1 16
22. B.O. Claus, E.A. Hoste, K. Colpaert, H. Robays, J. Decruyenaere, and J.J. De Waele Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy J Crit Care 28 2013 695 700
23. S.-J. Cho, I.-S. Yoon, and D.-D. Kim Obesity-related physiological changes and their pharmacokinetic consequences J Pharm Investig 43 2013 161 169
24. G.B. Forbes, and S.L. Welle Lean body mass in obesity Int J Obes 7 1983 99 107
25. W.K. Lagrand, E.R. van Slobbe-Bijlsma, and M.J. Schultz Haemodynamic monitoring of morbidly obese intensive care unit patients Neth J Med 71 2013 234 242
26. P. Poirier, T.D. Giles, G.A. Bray, Y. Hong, J.S. Stern, F.X. Pi-Sunyer, and et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation 113 2006 898 918
27. M. Rossi, M. Nannipieri, M. Anselmino, D. Guarino, F. Franzoni, and M. Pesce Subcutaneous adipose tissue blood flow and vasomotion in morbidly obese patients: long term effect of gastric bypass surgery Clin Hemorheol Microcirc 51 2011 159 167
28. S. Shah, G. Barton, and A. Fischer Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient J Intensive Care Soc 16 2015 147 153
29. I. Benedek, R. Blouin, and P. McNamara Serum protein binding and the role of increased α1-acid glycoprotein in moderately obese male subjects Br J Clin Pharmacol 18 1984 941 946
30. B. Suh, W.A. Craig, A.C. England, and R.L. Elliott Effect of free fatty acids on protein binding of antimicrobial agents J Infect Dis 143 1981 609 616
31. K. Morita, and A. Yamaji Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum α1-acid glycoprotein levels Ther Drug Monit 17 1995 107 112
32. H.Z. Zokufa, L.D. Solem, K.A. Rodvold, K.B. Crossley, J. Fischer, and J.C. Rotschafer The influence of serum albumin and α1-acid glycoprotein on vancomycin protein binding in patients with burn injuries J Burn Care Rehabil 10 1989 425 428
33. M. Suneja, and A.B. Kumar Obesity and perioperative acute kidney injury: a focused review J Crit Care 29 2014 694.e1-6
34. M. Kotlyar, and S.W. Carson Effects of obesity on the cytochrome P450 enzyme system Int J Clin Pharmacol Ther 37 1999 8 19
35. A. Keys, F. Fidanza, M.J. Karvonen, N. Kimura, and H.L. Taylor Indices of relative weight and obesity Int J Epidemiol 43 2014 655 665
36. M.P. Pai, and F.P. Paloucek The origin of the 'ideal' body weight equations Ann Pharmacother 34 2000 1066 1069
37. M.M. McCarron, and B.J. Devine Clinical pharmacy: case studies case number 25 gentamicin therapy Ann Pharmacother 8 1974 650 655
38. P. Amato, K.P. Keating, R.A. Quercia, and J. Karbonic Formulaic methods of estimating calorie requirements in mechanically ventilated obese patients: a reappraisal Nutr Clin Pract 10 1995 229 232
39. P. Han, S. Duffull, C. Kirkpatrick, and B. Green Dosing in obesity: a simple solution to a big problem Clin Pharmacol Ther 82 2007 505 508
40. D. Du Bois, and E. Du Bois Clinical calorimetry. Tenth paper. A formula to estimate the approximate surface area if height and weight be known Arch Intern Med 17 1916 863 871
41. J.S. Garrow, and J. Webster Quetelet's index (W/H2) as a measure of fatness Int J Obes 9 1984 147 153
42. World Health Organization Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee 1995 WHO Geneva, Switzerland Technical Report Series No. 854
43. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults 1998 National Heart, Lung, and Blood Institute (NHLBI) Bethesda, MD
44. B. Green, and S.B. Duffull What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58 2004 119 133
45. D.E. Salazar, and G.B. Corcoran Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass Am J Med 84 1988 1053 1060
46. J.A. Demirovic, A.B. Pai, and M.P. Pai Estimation of creatinine clearance in morbidly obese patients Am J Health Syst Pharm 66 2009 642 648
47. J.H. Martin, M.F. Fay, A. Udy, J. Roberts, C. Kirkpatrick, J. Ungerer, and et al. Pitfalls of using estimations of glomerular filtration rate in an intensive care population Intern Med J 41 2011 537 543
48. B.S. Rich, R. Keel, V.P. Ho, H. Turbendian, C.I. Afaneh, G.F. Dakin, and et al. Cefepime dosing in the morbidly obese patient population Obes Surg 22 2012 465 471
49. A.S. Alobaid, A. Brinkmann, O.R. Frey, A.C. Roehr, S. Luque, S. Grau, and et al. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients? J Antimicrob Chemother 71 2016 696 702
50. M. Chen, A.N. Nafziger, G.L. Drusano, L. Ma, and J.S. Bertino Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults Antimicrob Agents Chemother 50 2006 1222 1227
51. A.L. Ross, J.L. Tharp, G.R. Hobbs, R. McKnight, and A. Cumpston Evaluation of extended interval dosing aminoglycosides in the morbidly obese population Adv Pharmacol Sci 2013 2013 194389
52. F.S. Taccone, P.-F. Laterre, H. Spapen, T. Dugernier, I. Delattre, B. Layeux, and et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock Crit Care 14 2010 R53
53. M.P. Pai, A.N. Nafziger, and J.S. Bertino Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients Antimicrob Agents Chemother 55 2011 4006 4011
54. R.A. Blouin, L.A. Bauer, D.D. Miller, K.E. Record, and W.O. Griffen Vancomycin pharmacokinetics in normal and morbidly obese subjects Antimicrob Agents Chemother 21 1982 575 580
55. M.G. Kees, S. Weber, F. Kees, and T. Horbach Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients J Antimicrob Chemother 66 2011 2330 2335
56. A.M. Cook, C. Martin, V.R. Adams, and R.S. Morehead Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults Antimicrob Agents Chemother 55 2011 3240 3243
57. 2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring Clin Pharmacokinet 53 2014 753 762
58. S. Allard, M. Kinzig, G. Boivin, F. Sorgel, and M. LeBel Intravenous ciprofloxacin disposition in obesity Clin Pharmacol Ther 54 1993 368 373
59. A.A. Bhalodi, P.K. Papasavas, D.S. Tishler, D.P. Nicolau, and J.L. Kuti Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults Antimicrob Agents Chemother 57 2013 1144 1149
60. M.P. Pai Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults J Antimicrob Chemother 69 2014 190 199
61. B.H. Dvorchik, and D. Damphousse The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects J Clin Pharmacol 45 2005 48 56
62. M.P. Pai, J.P. Norenberg, T. Anderson, D.W. Goade, K.A. Rodvold, R.A. Telepak, and et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin Antimicrob Agents Chemother 51 2007 2741 2747
63. J.A. Roberts, R. Norris, D.L. Paterson, and J.H. Martin Therapeutic drug monitoring of antimicrobials Br J Clin Pharmacol 73 2012 27 36
64. A. Douglas, A.A. Udy, S.C. Wallis, P. Jarrett, J. Stuart, M. Lassig-Smith, and et al. Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery Antimicrob Agents Chemother 55 2011 5238 5242
65. J.A. Roberts, A.A. Udy, P. Jarrett, S.C. Wallis, W.W. Hope, R. Sharma, and et al. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients J Antimicrob Chemother 70 2015 1495 1502
66. S.C. Cheatham, M.R. Fleming, D.P. Healy, E.K. Chung, K.M. Shea, M.L. Humphrey, and et al. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit J Clin Pharmacol 54 2014 324 330
67. R. Kitzes-Cohen, D. Farin, G. Piva, and S.A. De Myttenaere-Bursztein Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients Int J Antimicrob Agents 19 2002 105 110
68. M. Hites, F.S. Taccone, F. Wolff, F. Cotton, M. Beumier, D. De Backer, and et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients Antimicrob Agents Chemother 57 2013 708 715
69. J.A. Roberts, and J. Lipman Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility Crit Care Med 41 2013 489 495
70. A.W. Sturm, N. Allen, K.D. Rafferty, D.N. Fish, E. Toschlog, M. Newell, and et al. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients Pharmacotherapy 34 2014 28 35
71. S.C. Cheatham, M.R. Fleming, D.P. Healy, C.E. Chung, K.M. Shea, M.L. Humphrey, and et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients Int J Antimicrob Agents 41 2013 52 56
72. P.A. Moise-Broder, A. Forrest, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections Clin Pharmacokinet 43 2004 925 942
73. E. Grace Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years J Antimicrob Chemother 67 2012 1305 1310
74. J.A. Roberts, F.S. Taccone, A.A. Udy, J.L. Vincent, F. Jacobs, and J. Lipman Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens Antimicrob Agents Chemother 55 2011 2704 2709
75. T.P. Lodise, B. Lomaestro, J. Graves, and G.L. Drusano Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity Antimicrob Agents Chemother 52 2008 1330 1336
76. R.S. Malone, D.N. Fish, E. Abraham, and I. Teitelbaum Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients Antimicrob Agents Chemother 45 2001 2949 2954
77. T.R. Utrup, E.W. Mueller, D.P. Healy, R.A. Callcut, J.D. Peterson, and W.E. Hurford High-dose ciprofloxacin for serious Gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration Ann Pharmacother 44 2010 1660 1664
78. D.M. Sabuda, K. Laupland, J. Pitout, B. Dalton, H. Rabin, T. Louie, and et al. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa Can J Infect Dis Med Microbiol 19 2008 413 418
79. S.M. Garonzik, J. Li, V. Thamlikitkul, D.L. Paterson, S. Shoham, J. Jacob, and et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients Antimicrob Agents Chemother 55 2011 3284 3294
80. N. Markou, S.L. Markantonis, E. Dimitrakis, D. Panidis, E. Boutzouka, S. Karatzas, and et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study Clin Ther 30 2008 143 151
81. D. Plachouras, M. Karvanen, L.E. Friberg, E. Papadomichelakis, A. Antoniadou, I. Tsangaris, and et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria Antimicrob Agents Chemother 53 2009 3430 3436
82. A.F. Mohamed, I. Karaiskos, D. Plachouras, M. Karvanen, K. Pontikis, B. Jansson, and et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill Antimicrob Agents Chemother 56 2012 4241 4249
83. D. Andes Pharmacokinetics and pharmacodynamics of antifungals Infect Dis Clin North Am 20 2006 679 697
84. N.D. Lopez, and K.M. Phillips Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration Pharmacotherapy 34 2014 e162 e168
85. E. Muhl, T. Martens, H. Iven, P. Rob, and H.-P. Bruch Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole Eur J Clin Pharmacol 56 2000 671 678
86. L.G. Cohen, A. DiBiasio, S.J. Lisco, and W.E. Hurford Fluconazole serum concentrations and pharmacokinetics in an obese patient Pharmacotherapy 17 1997 1023 1026
87. A. Zomp, P.B. Bookstaver, Y. Ahmed, J.E. Turner, and C. King Micafungin therapy in a critically ill, morbidly obese patient J Antimicrob Chemother 66 2011 2678 2680
88. J. Hiemenz, P. Cagnoni, D. Simpson, S. Devine, N. Chao, J. Keirns, and et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant Antimicrob Agents Chemother 49 2005 1331 1336
89. S. Grau, S. Luque, N. Campillo, E. Samsó, U. Rodríguez, C. García-Bernedo, and et al. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis J Antimicrob Chemother 70 2015 2854 2861
90. M. Hites, and F.S. Taccone Optimization of antibiotic therapy in the obese, critically ill patient Réanimation 24 2015 278 294